Boston Scientific announced its acquisition of Santa Rosa, California-based Claret Medical in a transaction that includes $220 million upfront and an additional potential reimbursement-based milestone payment of up to $50 million. The deal is expected to close before the end of the year.
Claret Medical developed the Sentinel Cerebral Embolic Protection System, which is used to protect a patient against stroke when undergoing a transcatheter aortic valve replacement (TAVR). Past studies indicate utilizing the Sentinel System during a TAVR procedure reduces incidences of all-cause mortality or stroke within one week of the interventional procedure.
"Through the development and commercialization of the Sentinel System, Claret Medical has successfully introduced a new layer of safety and peace of mind for physicians and their patients undergoing TAVR procedures," said Kevin Ballinger, president of interventional cardiology at Boston Scientific. "This acquisition will expand our commercial portfolio to include an important adjunctive offering aimed at improving TAVR patient outcomes. We also see potential for future use in other left heart and endovascular procedures such as mitral valve repair and replacement, left atrial appendage closure and pulmonary vein isolation ablation procedures for atrial fibrillation."
The Sentinel System received FDA clearance in 2017 and is currently the only device approved to protect patients against the risk of stroke during TAVR.
As a senior news writer for TriMed, Subrata covers cardiology, clinical innovation and healthcare business. She has a master’s degree in communication management and 12 years of experience in journalism and public relations.